SUPPLEMENTARY INFORMATION

Switching From Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE

Jonathan I. Silverberg,[1] Eric L. Simpson,[2] Andrew E. Pink,[3,4] Stephan Weidinger,[5] Gary Chan,[6] Pinaki Biswas,[7] Claire Clibborn,[8a] Erman Güler[9]

[1]The George Washington University School of Medicine and Health Sciences, 2300 I St NW, Washington, DC, USA; [2]Oregon Health & Science University, 3303 SW Bond Ave, Portland, OR, USA; [3]St. John's Institute of Dermatology, King's College London, 2 Lambeth Palace Rd, London, UK; [4]Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, UK; [5]University Hospital Schleswig-Holstein, Arnold-Heller-Str 3, Kiel, Germany; [6]Pfizer Inc., 500 Arcola Road, Groton, CT, USA; [7]Pfizer Inc., New York, 66 Hudson Boulevard, NY, USA; [8]Pfizer Ltd., Walton Oaks, Dorking Rd, Surrey, UK; [9]Pfizer Inc., Büyükdere Cd. No:199, 34394 Levent Istanbul, Turkey

[a]Affiliation at the time this analysis was conducted.

Table S1. Baseline demographics and clinical characteristics of dupilumab responders and nonresponders by efficacy outcomes at Week 26 of JADE DARE

	IGA 0/1[a] (*n* = 310)		**EASI-75 (*n* = 310)**		**PP-NRS4 (*n* = 311)**	
	Responders (*n* = 179)	Nonresponders (*n* = 131)	Responders (*n* = 254)	Nonresponders (*n* = 56)	Responders (*n* = 217)	Nonresponders (*n* = 94)
Age, mean ± SD, years	36 ± 13	37 ± 14	36 ± 13	38 ± 14	37 ± 14	34 ± 13
Female, *n* (%)	93 (52)	45 (34)	122 (48)	16 (29)	102 (47)	37 (39)
Race, *n (%)*						
White	127 (71)	80 (61)	171 (67)	36 (64)	148 (68)	59 (63)
Other[b]	52 (29)	51 (39)	83 (33)	20 (36)	69 (32)	35 (37)
Weight, mean ± SD, kg	76 ± 19	82 ± 23	77 ± 19	88 ± 26	78 ± 20	79 ± 23
IGA score of 4, *n* (%)	61 (34)	67 (51)	102 (40)	26 (46)	97 (45)	32 (34)

EASI, mean ± SD	25 ± 10	29 ± 13	27 ± 12	26 ± 12	28 ± 13	25 ± 10
PP-NRS, mean ± SD	7.1 ± 1.6[c]	7.0 ± 1.6[d]	7.0 ± 1.6[e]	7.1 ± 1.6[f]	7.2 ± 1.5[g]	6.6 ± 1.8[h]

[a]IGA response defined as IGA score of 0 (clear) or 1 (almost clear) and ≥2-point improvement from baseline

[b]Patients who identified as Black or African American, Asian, multiracial, or did not report their race

[c]*n* = 177

[d]*n* = 127

[e]*n* = 250

[f]*n* = 54

[g]*n* = 216

[h]*n* = 89

EASI Eczema Area and Severity Index, *EASI-75* ≥75% improvement from baseline in EASI, *IGA* Investigator's Global Assessment, *PP-NRS* Peak Pruritus Numerical Rating Scale, *PP-NRS4* ≥4-point improvement from baseline in PP-NRS

Table S2. Proportions of dupilumab responders and nonresponders at Week 26 of JADE DARE, based on various response criteria, who switched to abrocitinib 200 mg in JADE EXTEND[a]

Response criterion at Week 26 of JADE DARE	**Dupilumab-treated patients in JADE DARE who switched to abrocitinib 200 mg in JADE EXTEND (*N* = 309)[b]**	
	Dupilumab responders	**Dupilumab nonresponders**
IGA response[c], *n* (%)	178 (58)	131 (42)
EASI-50, *n* (%)	292 (94)	17 (6)
EASI-75, *n* (%)	254 (82)	55 (18)
EASI-90, *n* (%)	168 (54)	141 (46)
PP-NRS4, *n* (%)	217 (70)	92 (30)
PP-NRS 0/1, *n* (%)	113 (36)[d]	197 (64)[d]

[a]Data were collected during the end of treatment visit of JADE DARE/screening visit of JADE EXTEND

[b]Data were missing for some patients who did not have their efficacy responses measured at the end of treatment visit of JADE DARE/screening visit of JADE EXTEND

[c]IGA response defined as IGA score of 0 (clear) or 1 (almost clear) and ≥2-point improvement from baseline

[d]*N* = 310

DLQI Dermatology Life Quality Index, *DLQI 0/1* DLQI score of 0 or 1, *EASI* Eczema Area and Severity Index, *EASI-50* ≥50% improvement from baseline in EASI, *EASI-75* ≥75% improvement from baseline in EASI, *EASI-90* ≥90% improvement from baseline in EASI, *IGA* Investigator's Global Assessment, *PP-NRS* Peak Pruritus Numerical Rating Scale, *PP-NRS 0/1* PP-NRS score of 0 or 1, *PP-NRS4* ≥4-point improvement from baseline in PP-NRS